Glucose Metabolism Modification Induced by Radioligand Therapy with [<sup>177</sup>Lu]Lu/[<sup>90</sup>Y]Y-DOTATOC in Advanced Neuroendocrine Neoplasms: A Prospective Pilot Study within FENET-2016 Trial

Glucose Metabolism Modification Induced by Radioligand Therapy with [<sup>177</sup>Lu]Lu/[<sup>90</sup>Y]Y-DOTATOC in Advanced Neuroendocrine Neoplasms: A Prospective Pilot Study within FENET-2016 Trial

[<sup>18</sup>F]F-FDG (FDG) PET is emerging as a relevant diagnostic and prognostic tool in neuroendocrine neoplasms (NENs), as a simultaneous decrease in [<sup>68</sup>Ga]Ga-DOTA peptides and increase in FDG uptake (the “flip-flop” phenomenon) occurs during the natural histo...

Full description

Bibliographic Details
Main Authors: Luca Urso, Stefano Panareo, Angelo Castello, Maria Rosaria Ambrosio, Maria Chiara Zatelli, Matteo Caracciolo, Eugenia Tonini, Giorgia Valpiani, Alessandra Boschi, Licia Uccelli, Corrado Cittanti, Mirco Bartolomei
Format: Article
Language:English
Published: MDPI AG 2022-09-01
Series:Pharmaceutics
Subjects:
neuroendocrine neoplasms
NEN
NET
radioligand therapy
RLT
peptide receptor radionuclide therapy
Online Access:https://www.mdpi.com/1999-4923/14/10/2009

Internet

https://www.mdpi.com/1999-4923/14/10/2009

Similar Items